Abciximab (ReoPro)

A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.

Also Known As:

Networked: 1218 relevant articles (162 outcomes, 361 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Stone, Gregg W: 50 articles (12/2016 - 03/2002)
2.	Mehran, Roxana: 35 articles (10/2016 - 09/2003)
3.	Kastrati, Adnan: 30 articles (12/2016 - 03/2002)
4.	Tcheng, James E: 26 articles (07/2009 - 03/2002)
5.	Mehilli, Julinda: 25 articles (12/2013 - 03/2002)
6.	Topol, Eric J: 25 articles (02/2010 - 01/2002)
7.	Dudek, Dariusz: 24 articles (01/2015 - 01/2002)
8.	Neumann, Franz-Josef: 23 articles (02/2014 - 05/2002)
9.	Schömig, Albert: 23 articles (08/2013 - 03/2002)
10.	Grines, Cindy L: 22 articles (07/2010 - 03/2002)

Related Diseases

1.	ST Elevation Myocardial Infarction 06/01/2012 - "The present updated meta-analysis showed that IC administration of abciximab is associated with significant benefits in myocardial perfusion, but not in clinical outcome at short-term follow-up as compared to IV abciximab administration, without any excess of major bleedings in STEMI patients undergoing primary PCI. " 03/01/2012 - "IC abciximab in the setting of pPCI for ST-segment elevation myocardial infarction may be beneficial for patients with higher risk profiles." 12/01/2011 - "This meta-analysis shows that early upstream administration of abciximab in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI) is associated with significant benefits in terms of pre-procedural epicardial re-canalization and ST-segment resolution, which translates in to significant mortality benefits at long-term follow-up." 01/01/2011 - "In pPCI-treated STEMI patients treated with abciximab, IC bolus administration resulted in a significant reduction in mortality, TVR and MI compared to IV bolus administration." 05/05/2009 - "Abciximab has been shown to provide significant benefits in PPCI for STEMI. "
2.	Myocardial Infarction 12/01/2011 - "Furthermore, early abciximab administration was associated with a significant improvement in pre-procedural thrombolysis in myocardial infarction (TIMI) 3 flow (21.6% vs. 10.1%, P < 0.0001), post-procedural TIMI 3 flow (90% vs. 84.8%, P = 0.04), an improvement in myocardial perfusion as evaluated by post-procedural myocardial blush grade (MBG) 3 (52.0% vs. 43.2%, P = 0.03) and ST-segment resolution (58.4% vs. 43.5%, P < 0.0001) and significantly less distal embolization (10.1% vs. 16.2%, P = 0.02). " 11/01/2006 - "There was also a numerical but not statistically significant reduction in myocardial infarction rate using abciximab bolus-only compared with placebo. " 05/15/2001 - "The present study investigated whether the reperfusion efficacy of abciximab relates to modifications of clot architecture in patients admitted for acute myocardial infarction (AMI). " 12/01/2015 - "Intralesion abciximab administration was associated with improved angiographic myocardial reperfusion in terms of thrombolysis in myocardial infarction (TIMI) flow (3 [3-3] vs 3 [2-3], P = .040), corrected TIMI frame count (12 ± 5 vs 17 ± 16, P = .021), and myocardial blush grade (3 [2-3] vs 3 [2-3], P = .035). " 11/01/2007 - "Use and efficacy of abciximab in an unselected population with acute myocardial infarction treated with primary angioplasty: data from AMI-Florence registry."
3.	Thrombosis (Thrombus) 04/01/1999 - "This staged approach, with abciximab used alone to reduce thrombus load, is a new treatment for vein graft lesions containing massive thrombus." 05/01/2009 - "This study investigated the relationship between abciximab treatment and presence of LV thrombus in the first few days after primary stenting. " 12/01/2008 - "This study evaluates risk factors for thrombus formation and assesses the efficacy and safety of abciximab for clot dissolution. " 12/01/2000 - "This is considerably less than the 80% level of receptor inhibition that has been proposed to prevent coronary thrombus formation in animal models and that has been achieved in clinical trials with abciximab. " 01/01/2020 - "Life after abciximab; what's next for intracoronary thrombus?"
4.	Infarction (Infarctions) 08/01/2020 - "The aim of the study was to investigate that: uses of intra venous Abciximab, does not improve coronary flow in patients with MI that develop sub optimal flow after primary PCI within 30 minutes, but the improvement need 12 to 24 hour as founded in other studies, and its beneficial effect is related to early improvement in LV function and decrease of re-infarction and re-hospitalization. " 05/02/2012 - "Patients randomized to intracoronary abciximab also had a significant reduction in absolute infarct mass (median, 18.7 g [IQR, 7.4-31.3 g]; n = 184, vs 24.0 g [IQR, 12.1-34.2 g]; n = 175; P = .03) but not abnormal wall motion score (median, 7.0 [IQR, 2.0-10.0]; n = 188, vs 8.0 [IQR, 3.0-10.0]; n = 184; P = .08). " 05/02/2012 - "Patients randomized to intracoronary abciximab compared with no abciximab had a significant reduction in 30-day infarct size (median, 15.1%; interquartile range [IQR], 6.8%-22.7%; n = 181, vs 17.9% [IQR, 10.3%-25.4%]; n = 172; P = .03). " 03/08/2012 - "The Early group showed a significantly higher STR (94.5% vs. 80.0%, P=0.04) and a larger reduction in infarct transmurality (-9.2 ± 7.0% vs. -5.9 ± 6.4%; P=0.03), while a larger reduction in IS was observed only in patients with ECG-to-Cath Lab time >60 min. Early abciximab administration did not lead to a smaller IS at 6-month DE-MRI, and was associated with a significant reduction in IS and transmurality only in patients with longer transportation time, warranting further investigation in this patient subset." 05/01/2011 - "Intracoronary (IC) abciximab bolus application during PCI results in high local drug concentration, improved perfusion, reduction of infarct size, and less microvascular obstruction early after infarction. "
5.	Hemorrhage 06/01/2012 - "As compared to IV route, IC abciximab was associated with a significant improvement in myocardial perfusion (OR [95% CI]=1.76 [1.28-2.42], p<0.001), without significant benefits in terms of mortality (OR [95% CI]=0.85 [0.59-1.23], p=0.39), reinfarction (OR [95% CI]=0.79 [0.46-1.33], p=0.37), or major bleeding complications (OR [95% CI]=1.19 [0.76-1.87], p=0.44). " 08/01/2003 - "Although abciximab increases the risk of bleeding in all patients, the increase in relative risk is not significantly greater in patients with CRI. " 10/01/2008 - "Abciximab thought to be safe and effective in initial case series and early trials, has not been shown to improve outcomes in AIS, and is associated with higher rates of hemorrhage. " 01/01/2016 - "The use of intravenous abciximab was not associated with improved clinical outcomes up to 1-year among patients undergoing SVG PCI, but was related to more bleeding." 08/01/2009 - "The purpose of the present study was to compare ex vivo antiplatelet activity, angiographic outcome, and bleeding complications between biogeneric and branded abciximab. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	Platelet Membrane Glycoprotein IIb
3.	Tirofiban (Aggrastat)
4.	Abciximab (ReoPro)
5.	Glycoproteins (Glycoprotein)
6.	Aspirin (Acetylsalicylic Acid)
7.	Eptifibatide (Integrilin)
8.	Clopidogrel (Plavix)
9.	reteplase
10.	Platelet Membrane Glycoproteins

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Therapeutics
3.	Stents
4.	Thrombectomy
5.	Intravenous Administration